|
" Pemphigus foliaceus in a patient with gastrointestinal stromal tumor treated with adjuvant imatinib mesylate "
Lewis, Hal A; Chen, David Y; Rosman, Ilana S; Picus, Joel; Anadkat, Milan J
| Document Type
|
:
|
AL
|
| Record Number
|
:
|
923226
|
| Doc. No
|
:
|
LA9n18x89m
|
| Language of Document
|
:
|
English
|
| Main Entry
|
:
|
Lewis, Hal A; Chen, David Y; Rosman, Ilana S; Picus, Joel; Anadkat, Milan J
|
| Title & Author
|
:
|
Pemphigus foliaceus in a patient with gastrointestinal stromal tumor treated with adjuvant imatinib mesylate [Article]\ Lewis, Hal A; Chen, David Y; Rosman, Ilana S; Picus, Joel; Anadkat, Milan J
|
| Title of Periodical
|
:
|
Dermatology Online Journal
|
| Volume/ Issue Number
|
:
|
26/6
|
| Date
|
:
|
2020
|
| Abstract
|
:
|
Pemphigus is an autoimmune bullous disease with a number of described associations, including medications, which have been grouped into three structural categories - thiol drugs, phenol drugs, and drugs with neither functional group [1]. Discontinuation of the offending medication is considered a mainstay of therapy. We report a patient in whom the onset of pemphigus foliaceus was associated with initiation of imatinib mesylate adjuvant therapy in a patient with resected gastrointestinal stromal tumor (GIST). Imatinib was continued because of the survival benefit to the patient with a resected, high risk GIST. Treatment with rituximab resulted in near resolution of his blistering rash and follow up enzyme-linked immunosorbent assay (ELISA) demonstrated reference range immunoreactivity for both desmoglein 1 and desmoglein 3. After dose increase of imatinib therapy owing to tumor growth, the patient subsequently again developed a similar eruption. Re-biopsy and ELISA were consistent with recurrence of pemphigus. In conclusion, although the patient's pemphigus was cleared with a single cycle of rituximab infusions while continuing imatinib therapy, the disease returned after imatinib dose was increased a year later, suggesting a dose-response relationship.
|
| |